Department of Psychiatry, Yale University School of Medicine, New Haven, United States; Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, United States
Department of Psychiatry, Yale University School of Medicine, New Haven, United States
Clara Fonteneau
Department of Psychiatry, Yale University School of Medicine, New Haven, United States
Joshua B Burt
RBNC Therapeutics, San Francisco, United States
Zailyn Tamayo
Department of Psychiatry, Yale University School of Medicine, New Haven, United States
Jure Demšar
Department of Psychology, University of Ljubljana, Ljubljana, Slovenia; Faculty of Computer and Information Science, University of Ljubljana, Ljubljana, Slovenia
Department of Psychiatry, Yale University School of Medicine, New Haven, United States; Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, United States
Aleksandar Savić
Department of Psychiatry, University of Zagreb, Zagreb, Croatia
The Janssen Pharmaceutical Companies of Johnson and Johnson, San Francisco, United States
Grega Repovš
Department of Psychiatry, University of Zagreb, Zagreb, Croatia
Youngsun T Cho
Department of Psychiatry, Yale University School of Medicine, New Haven, United States; Child Study Center, Yale University School of Medicine, New Haven, United States
Christopher Pittenger
Department of Psychiatry, Yale University School of Medicine, New Haven, United States; Child Study Center, Yale University School of Medicine, New Haven, United States
Department of Psychiatry, Yale University School of Medicine, New Haven, United States; Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, United States; Department of Physics, Yale University, New Haven, United States
Department of Psychiatry, Yale University School of Medicine, New Haven, United States; Interdepartmental Neuroscience Program, Yale University School of Medicine, New Haven, United States; Department of Psychology, Yale University School of Medicine, New Haven, United States
Difficulties in advancing effective patient-specific therapies for psychiatric disorders highlight a need to develop a stable neurobiologically grounded mapping between neural and symptom variation. This gap is particularly acute for psychosis-spectrum disorders (PSD). Here, in a sample of 436 PSD patients spanning several diagnoses, we derived and replicated a dimensionality-reduced symptom space across hallmark psychopathology symptoms and cognitive deficits. In turn, these symptom axes mapped onto distinct, reproducible brain maps. Critically, we found that multivariate brain-behavior mapping techniques (e.g. canonical correlation analysis) do not produce stable results with current sample sizes. However, we show that a univariate brain-behavioral space (BBS) can resolve stable individualized prediction. Finally, we show a proof-of-principle framework for relating personalized BBS metrics with molecular targets via serotonin and glutamate receptor manipulations and neural gene expression maps derived from the Allen Human Brain Atlas. Collectively, these results highlight a stable and data-driven BBS mapping across PSD, which offers an actionable path that can be iteratively optimized for personalized clinical biomarker endpoints.